• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adaptive treatment using neratinib shows benefit in early breast cancer

byNeil D'SouzaandShaidah Deghan, MSc. MD
July 10, 2016
in Oncology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The addition of neratinib to standard therapy was more likely to result in higher pathological complete response rates compared to standard therapy with trastuzamab in HER-2 positive, hormone receptor negative breast cancer patients.

2. Toxicity associated with neratinib was mainly gastrointestinal related, but was manageable with medication.

Evidence Rating Level: 1 (Excellent)      

Study Rundown:  Breast cancer is a heterogeneous disease presenting challenges for diagnosis and subsequent management. Using the unique biologic properties of tumours, genetic testing can aid in identifying breast cancer subtypes and, in turn, direct targeted therapies. Neratinib is a tyrosine kinase inhibitor, which has shown promising results against HER-2 positive metastatic breast cancer. This study aimed to rapidly identify these subtypes, and then randomize patients to have neratinib and paclitaxel, versus standard therapy of paclitaxel and trastuzamab. The primary endpoint was pathological complete response (absence of residual cancer in the breast or lymph nodes at the time of surgery). The results showed a favourable pathologic complete response rate in the neratinib group compared to the control group for HER-2 positive, hormone-receptor negative breast cancers. The associated side effects were mainly gastrointestinal related (diarrhea), and was managed adequately with anti-diarrheal medication.  The strengths of this study was the randomization of patients, and having data supporting adaptive therapy which allows patients to have a more personalized approach to their care and limits the exposure to therapies that may be ineffective or have increase adverse effects.  Further, adaptive approach can streamline future randomized controlled trials.  The limitation of this study was the small number of patients involved in the randomization.

Click to read the study, published in NEJM

Relevant Reading:  The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research.

In-Depth [randomized controlled trial]: This study was an adaptive randomized controlled trial aimed to match experimental therapies with breast cancer subtypes.  The study subdivided early stage patients according to biomarkers status with respect to HER-2, hormone receptors and a 70-gene assay. Patients underwent randomization according to subtype and experimental therapy that would accordingly be best suited. Neratinib was evaluated against 10 biomarkers and control. The primary endpoint was complete pathological response.  MRI was used to assess degree of response, and Bayesian predictive probabilities were used to estimate success in subsequent phase 3 study if a success threshold of 85% was reached.

RELATED REPORTS

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

Combination mammography and breast tomosynthesis improves breast cancer screening [Classics Series]

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

A total of 127 patients were included in the neratnib-paclitaxel group and 78 patients to the neratinib-paclitaxel-trastuzamab group. The estimated complete pathological response rate was 56% (95% Bayesian probability interval (PI) 37-73%) among the neratinib group, versus 33% (95%PI 11-54%) in the control group. The probability of neratinib being superior to control was 95%, and was estimated to have an 79% predicted probability of success in a phase 3 trial involving at least 300 patients.

In terms of toxicity, diarrhea was the most common adverse event, with grade 3 or 4 diarrhea in 38% of the patients in the neratinib group. No deaths occurred as result of adding neratinib.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancer
Previous Post

The VALIANT trial: Valsartan vs. captopril in patients with acute myocardial infarction and heart failure [Classic Series]

Next Post

2 Minute Medicine Rewind July 11, 2016

RelatedReports

#VisualAbstract: Capivasertib in addition to fulvestrant improves  progression-free survival in ER⁺ advanced breast cancer
StudyGraphics

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

August 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Combination mammography and breast tomosynthesis improves breast cancer screening [Classics Series]

August 16, 2022
Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ
Oncology

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

August 15, 2022
Characteristic differences between young children and adolescents who die by suicide
Weekly Rewinds

2 Minute Medicine Rewind August 8, 2022

August 15, 2022
Next Post
Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses

2 Minute Medicine Rewind July 11, 2016

UTI associated with increased risk of preeclampsia

Study review diagnosis and management of hypertension in children

Post-surgical wound complications more common in obese ovarian cancer patients

Common surgical procedures linked with increased risk of chronic opioid use

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
  • Removal of asymptomatic kidney stones reduces risk of relapse
  • The CDC implements a community-level metrics program to inform COVID-19 policy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.